Additionally, the 36-month beta value for VCYT is 1.64. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for VCYT is 75.65M and currently, short sellers hold a 4.11% ratio of that float. The average trading volume of VCYT on August 30, 2024 was 927.04K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VCYT) stock’s latest price update
Veracyte Inc (NASDAQ: VCYT)’s stock price has increased by 1.01 compared to its previous closing price of 31.62. However, the company has seen a 2.83% increase in its stock price over the last five trading sessions. businesswire.com reported 2024-08-26 that SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 2:35 p.m. Eastern Time. A live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay o.
VCYT’s Market Performance
VCYT’s stock has risen by 2.83% in the past week, with a monthly rise of 33.08% and a quarterly rise of 52.17%. The volatility ratio for the week is 3.07% while the volatility levels for the last 30 days are 5.70% for Veracyte Inc The simple moving average for the last 20 days is 8.73% for VCYT stock, with a simple moving average of 33.09% for the last 200 days.
Analysts’ Opinion of VCYT
Many brokerage firms have already submitted their reports for VCYT stocks, with Needham repeating the rating for VCYT by listing it as a “Buy.” The predicted price for VCYT in the upcoming period, according to Needham is $33 based on the research report published on February 23, 2024 of the current year 2024.
Scotiabank gave a rating of “Sector Outperform” to VCYT, setting the target price at $33 in the report published on January 05th of the previous year.
VCYT Trading at 25.80% from the 50-Day Moving Average
After a stumble in the market that brought VCYT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.17% of loss for the given period.
Volatility was left at 5.70%, however, over the last 30 days, the volatility rate increased by 3.07%, as shares surge +39.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +49.18% upper at present.
During the last 5 trading sessions, VCYT rose by +2.83%, which changed the moving average for the period of 200-days by +43.87% in comparison to the 20-day moving average, which settled at $29.82. In addition, Veracyte Inc saw 16.10% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VCYT starting from JONES EVAN/ FA, who sale 27,188 shares at the price of $32.20 back on Aug 13 ’24. After this action, JONES EVAN/ FA now owns 5,173 shares of Veracyte Inc, valued at $875,565 using the latest closing price.
JONES EVAN/ FA, the Director of Veracyte Inc, sale 20,457 shares at $32.20 during a trade that took place back on Aug 13 ’24, which means that JONES EVAN/ FA is holding 34,343 shares at $658,801 based on the most recent closing price.
Stock Fundamentals for VCYT
Current profitability levels for the company are sitting at:
- -0.08 for the present operating margin
- 0.66 for the gross margin
The net margin for Veracyte Inc stands at -0.14. The total capital return value is set at -0.03. Equity return is now at value -4.88, with -4.51 for asset returns.
Based on Veracyte Inc (VCYT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 2.43. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -8171.0.
Currently, EBITDA for the company is 15.12 million with net debt to EBITDA at -3.46. When we switch over and look at the enterprise to sales, we see a ratio of 5.6. The receivables turnover for the company is 7.94for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.44.
Conclusion
In conclusion, Veracyte Inc (VCYT) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
